Course of the modified rodnan skin thickness score in systemic sclerosis clinical trials

Analysis of three large multicenter, double-blind, randomized controlled trials

Sogol Amjadi, Paul Maranian, Daniel E. Furst, Philip J. Clements, Kee Wong Weng, Arnold Postlethwaite, Puja P. Khanna, Dinesh Khanna

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Objective. To assess the course of the modified Rodnan skin thickness score (MRSS) in 3 large, multi-center, double-blind, randomized controlled trials (RCTs) of patients with diffuse cutaneous systemic sclerosis (dcSSc) with different baseline disease durations, as defined from the date of onset of the first dcSSc symptom (excluding Raynaud's phenomenon) or from the date of onset of the first dcSSc-related symptom (including Raynaud's phenomenon). Methods. Data from 3 RCTs examining high-dose versus low-dose D-penicillamine (D-Pen Trial), recombinant human relaxin versus placebo (Relaxin Trial), and oral bovine type I collagen versus placebo (Collagen Trial) treatment in patients with dcSSc were pooled and analyzed. Patients were divided into 5 groups according to their disease duration at baseline. The linear mixed model for correlated data was used to model the 2 predictors of MRSS: time in study (expressed in months after baseline) and baseline disease duration (expressed in months, calculated from the date of onset of the first symptom characteristic of dcSSc with and without Raynaud's phenomenon). Results. At study entry, the mean MRSS value was 21.0 in the D-Pen Trial cohort, 27.3 in the Relaxin Trial cohort, and 26.1 in the Collagen Trial cohort. Time in study was a significant predictor of improvement in MRSS regardless of the disease duration at baseline (P < 0.0001). Patients with a disease duration of ≥24 months showed a greater rate of decline as compared with patients with a disease duration of <24 months (P < 0.05). Similar results were obtained when disease duration was reclassified by including the time of the first Raynaud's phenomenon symptom in the definition. Conclusion. Our study confirms recent findings that in patients entered into these 3 RCTs, skin thickening did not follow the same trend in natural history as that seen in the dcSSc populations entered into early, open longitudinal studies previously reported. These findings have important implications for study design, in which "prevention of worsening" is the main objective.

Original languageEnglish (US)
Pages (from-to)2490-2498
Number of pages9
JournalArthritis and Rheumatism
Volume60
Issue number8
DOIs
StatePublished - Aug 1 2009

Fingerprint

Systemic Scleroderma
Diffuse Scleroderma
Randomized Controlled Trials
Clinical Trials
Raynaud Disease
Skin
Relaxin
Collagen
Placebos
Penicillamine
Collagen Type I
Natural History
Longitudinal Studies
Linear Models
Population

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Course of the modified rodnan skin thickness score in systemic sclerosis clinical trials : Analysis of three large multicenter, double-blind, randomized controlled trials. / Amjadi, Sogol; Maranian, Paul; Furst, Daniel E.; Clements, Philip J.; Weng, Kee Wong; Postlethwaite, Arnold; Khanna, Puja P.; Khanna, Dinesh.

In: Arthritis and Rheumatism, Vol. 60, No. 8, 01.08.2009, p. 2490-2498.

Research output: Contribution to journalArticle

Amjadi, Sogol ; Maranian, Paul ; Furst, Daniel E. ; Clements, Philip J. ; Weng, Kee Wong ; Postlethwaite, Arnold ; Khanna, Puja P. ; Khanna, Dinesh. / Course of the modified rodnan skin thickness score in systemic sclerosis clinical trials : Analysis of three large multicenter, double-blind, randomized controlled trials. In: Arthritis and Rheumatism. 2009 ; Vol. 60, No. 8. pp. 2490-2498.
@article{7a5c410482514a93a4f3f0215d4d851e,
title = "Course of the modified rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double-blind, randomized controlled trials",
abstract = "Objective. To assess the course of the modified Rodnan skin thickness score (MRSS) in 3 large, multi-center, double-blind, randomized controlled trials (RCTs) of patients with diffuse cutaneous systemic sclerosis (dcSSc) with different baseline disease durations, as defined from the date of onset of the first dcSSc symptom (excluding Raynaud's phenomenon) or from the date of onset of the first dcSSc-related symptom (including Raynaud's phenomenon). Methods. Data from 3 RCTs examining high-dose versus low-dose D-penicillamine (D-Pen Trial), recombinant human relaxin versus placebo (Relaxin Trial), and oral bovine type I collagen versus placebo (Collagen Trial) treatment in patients with dcSSc were pooled and analyzed. Patients were divided into 5 groups according to their disease duration at baseline. The linear mixed model for correlated data was used to model the 2 predictors of MRSS: time in study (expressed in months after baseline) and baseline disease duration (expressed in months, calculated from the date of onset of the first symptom characteristic of dcSSc with and without Raynaud's phenomenon). Results. At study entry, the mean MRSS value was 21.0 in the D-Pen Trial cohort, 27.3 in the Relaxin Trial cohort, and 26.1 in the Collagen Trial cohort. Time in study was a significant predictor of improvement in MRSS regardless of the disease duration at baseline (P < 0.0001). Patients with a disease duration of ≥24 months showed a greater rate of decline as compared with patients with a disease duration of <24 months (P < 0.05). Similar results were obtained when disease duration was reclassified by including the time of the first Raynaud's phenomenon symptom in the definition. Conclusion. Our study confirms recent findings that in patients entered into these 3 RCTs, skin thickening did not follow the same trend in natural history as that seen in the dcSSc populations entered into early, open longitudinal studies previously reported. These findings have important implications for study design, in which {"}prevention of worsening{"} is the main objective.",
author = "Sogol Amjadi and Paul Maranian and Furst, {Daniel E.} and Clements, {Philip J.} and Weng, {Kee Wong} and Arnold Postlethwaite and Khanna, {Puja P.} and Dinesh Khanna",
year = "2009",
month = "8",
day = "1",
doi = "10.1002/art.24681",
language = "English (US)",
volume = "60",
pages = "2490--2498",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Course of the modified rodnan skin thickness score in systemic sclerosis clinical trials

T2 - Analysis of three large multicenter, double-blind, randomized controlled trials

AU - Amjadi, Sogol

AU - Maranian, Paul

AU - Furst, Daniel E.

AU - Clements, Philip J.

AU - Weng, Kee Wong

AU - Postlethwaite, Arnold

AU - Khanna, Puja P.

AU - Khanna, Dinesh

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Objective. To assess the course of the modified Rodnan skin thickness score (MRSS) in 3 large, multi-center, double-blind, randomized controlled trials (RCTs) of patients with diffuse cutaneous systemic sclerosis (dcSSc) with different baseline disease durations, as defined from the date of onset of the first dcSSc symptom (excluding Raynaud's phenomenon) or from the date of onset of the first dcSSc-related symptom (including Raynaud's phenomenon). Methods. Data from 3 RCTs examining high-dose versus low-dose D-penicillamine (D-Pen Trial), recombinant human relaxin versus placebo (Relaxin Trial), and oral bovine type I collagen versus placebo (Collagen Trial) treatment in patients with dcSSc were pooled and analyzed. Patients were divided into 5 groups according to their disease duration at baseline. The linear mixed model for correlated data was used to model the 2 predictors of MRSS: time in study (expressed in months after baseline) and baseline disease duration (expressed in months, calculated from the date of onset of the first symptom characteristic of dcSSc with and without Raynaud's phenomenon). Results. At study entry, the mean MRSS value was 21.0 in the D-Pen Trial cohort, 27.3 in the Relaxin Trial cohort, and 26.1 in the Collagen Trial cohort. Time in study was a significant predictor of improvement in MRSS regardless of the disease duration at baseline (P < 0.0001). Patients with a disease duration of ≥24 months showed a greater rate of decline as compared with patients with a disease duration of <24 months (P < 0.05). Similar results were obtained when disease duration was reclassified by including the time of the first Raynaud's phenomenon symptom in the definition. Conclusion. Our study confirms recent findings that in patients entered into these 3 RCTs, skin thickening did not follow the same trend in natural history as that seen in the dcSSc populations entered into early, open longitudinal studies previously reported. These findings have important implications for study design, in which "prevention of worsening" is the main objective.

AB - Objective. To assess the course of the modified Rodnan skin thickness score (MRSS) in 3 large, multi-center, double-blind, randomized controlled trials (RCTs) of patients with diffuse cutaneous systemic sclerosis (dcSSc) with different baseline disease durations, as defined from the date of onset of the first dcSSc symptom (excluding Raynaud's phenomenon) or from the date of onset of the first dcSSc-related symptom (including Raynaud's phenomenon). Methods. Data from 3 RCTs examining high-dose versus low-dose D-penicillamine (D-Pen Trial), recombinant human relaxin versus placebo (Relaxin Trial), and oral bovine type I collagen versus placebo (Collagen Trial) treatment in patients with dcSSc were pooled and analyzed. Patients were divided into 5 groups according to their disease duration at baseline. The linear mixed model for correlated data was used to model the 2 predictors of MRSS: time in study (expressed in months after baseline) and baseline disease duration (expressed in months, calculated from the date of onset of the first symptom characteristic of dcSSc with and without Raynaud's phenomenon). Results. At study entry, the mean MRSS value was 21.0 in the D-Pen Trial cohort, 27.3 in the Relaxin Trial cohort, and 26.1 in the Collagen Trial cohort. Time in study was a significant predictor of improvement in MRSS regardless of the disease duration at baseline (P < 0.0001). Patients with a disease duration of ≥24 months showed a greater rate of decline as compared with patients with a disease duration of <24 months (P < 0.05). Similar results were obtained when disease duration was reclassified by including the time of the first Raynaud's phenomenon symptom in the definition. Conclusion. Our study confirms recent findings that in patients entered into these 3 RCTs, skin thickening did not follow the same trend in natural history as that seen in the dcSSc populations entered into early, open longitudinal studies previously reported. These findings have important implications for study design, in which "prevention of worsening" is the main objective.

UR - http://www.scopus.com/inward/record.url?scp=68049111578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049111578&partnerID=8YFLogxK

U2 - 10.1002/art.24681

DO - 10.1002/art.24681

M3 - Article

VL - 60

SP - 2490

EP - 2498

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 8

ER -